At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
nab-paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer
In Brief
A Phase 2 clinical trial evaluating nab-paclitaxel, Bevacizumab, and 1 other intervention for Breast Cancer. Completed, enrolled 29 participants across 6 sites.
Detailed Summary
This trial combines trastuzumab and bevacizumab monoclonal antibodies, with ABI-007 and carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers demonstrating HER2 gene amplification. It is hoped that this novel combination will result in increased pathologic response rates that will translate into long term outcome improvements in HER2 positive patients with locally advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsCelgene Corporation, Genentech, Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedOct 2006
Primary CompletionApr 2008
Study CompletionDec 2011
TodayJul 2026
First PostedOct 26, 2006
Enrollment StartOct 1, 2006
Primary CompletionApr 1, 2008
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.7 years ago
Interventions
nab-paclitaxeldrug
ABI-007
Bevacizumabdrug
Bevacizumab
Trastuzumabdrug
Trastuzumab